Literature DB >> 33884210

Therapeutic Plasma Exchange Application in Children Requires Individual Decision.

Gürkan Atay1, Demet Demirkol1,2.   

Abstract

Therapeutic plasma exchange (TPE) is a treatment administered with the aim of removing a pathogenic material or compound causing morbidity in a variety of neurologic, hematologic, renal, and autoimmune diseases. In this study, we aimed to assess the indications, efficacy, reliability, complications, and treatment response of pediatric patients for TPE. This retrospective study analyzed data from 39 patients aged from 0 to 18 years who underwent a total of 172 TPE sessions from January 2015 to April 2018 in a tertiary pediatric intensive care unit. Indications for TPE were, in order of frequency, macrophage activation syndrome (28.2%, n  = 11), renal transplantation rejection (15.4%, n  = 6), liver failure (15.4%, n  = 6), Guillain-Barre's syndrome (15%, n  = 6), hemolytic uremic syndrome (7.7%, n  = 3), acute demyelinating disease (7.7%, n  = 3), septic shock (5.1%, n  = 2), and intoxication (5.1%, n  = 2). No patient had any adverse event related to the TPE during the procedure. The TPE session was ended prematurely in one patient due to insufficient vascular access and lack of blood flow (2.6%). In the long term, thrombosis due to the indwelling central catheter occurred (5.1%, n  = 2). TPE appears to be an effective first-stage or supplementary treatment in a variety of diseases, may be safely used in pediatric patients, and there are significant findings that its area of use will increase. In experienced hands and when assessed carefully, it appears that the rate of adverse reactions and vascular access problems may be low enough to be negligible. Thieme. All rights reserved.

Entities:  

Keywords:  indications; pediatric; therapeutic plasma exchange

Year:  2020        PMID: 33884210      PMCID: PMC8052102          DOI: 10.1055/s-0040-1714098

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  15 in total

Review 1.  Therapeutic plasma exchange and cytapheresis in pediatric patients.

Authors:  J B Gorlin
Journal:  Transfus Sci       Date:  1999-08

2.  Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors: 
Journal:  Lancet       Date:  1997-01-25       Impact factor: 79.321

3.  Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high-volume plasmapheresis in fulminant hepatic failure.

Authors:  F S Larsen; B A Hansen; E Ejlersen; N H Secher; J O Clemmesen; N Tygstrup; G M Knudsen
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-03       Impact factor: 2.566

4.  Comparison of Molecular Adsorbents Recirculating System (MARS) dialysis with combined plasma exchange and haemodialysis in children with acute liver failure.

Authors:  Betti Schaefer; Franz Schaefer; Guido Engelmann; Jochen Meyburg; Karl Heinz Heckert; Markus Zorn; Claus Peter Schmitt
Journal:  Nephrol Dial Transplant       Date:  2011-03-18       Impact factor: 5.992

Review 5.  Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  I Cortese; V Chaudhry; Y T So; F Cantor; D R Cornblath; A Rae-Grant
Journal:  Neurology       Date:  2011-01-18       Impact factor: 9.910

6.  Complications of apheresis in children.

Authors:  Bruno Michon; Albert Moghrabi; Rochelle Winikoff; Stéphane Barrette; Mark L Bernstein; Josette Champagne; Michèle David; Michel Duval; Heather A Hume; Nancy Robitaille; André Bélisle; Martin A Champagne
Journal:  Transfusion       Date:  2007-10       Impact factor: 3.157

7.  Regional citrate anticoagulation with calcium replacement in pediatric apheresis.

Authors:  Katie Sigler; Ji Lee; Poyyapakkam Srivaths
Journal:  J Clin Apher       Date:  2017-10-13       Impact factor: 2.821

8.  Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?

Authors:  Demet Demirkol; Dincer Yildizdas; Benan Bayrakci; Bulent Karapinar; Tanil Kendirli; Tolga F Koroglu; Oguz Dursun; Nilgün Erkek; Hakan Gedik; Agop Citak; Selman Kesici; Metin Karabocuoglu; Joseph A Carcillo
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

9.  Plasmapheresis in neurological disorders: Experience from a tertiary care hospital in South India.

Authors:  V Abdul Gafoor; James Jose; K Saifudheen; Mohamed Musthafa
Journal:  Ann Indian Acad Neurol       Date:  2015 Jan-Mar       Impact factor: 1.383

10.  Therapeutic plasma exchange in pediatric patients of Guillain-Barre syndrome: Experience from a Tertiary Care Centre.

Authors:  Maitrey Gajjar; Tarak Patel; Nidhi Bhatnagar; Meghana Solanki; Vaidehi Patel; Shital Soni
Journal:  Asian J Transfus Sci       Date:  2016 Jan-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.